ArticleAmerican journal of clinical and experimental immunology2016
Etanercept in the treatment of refractory SAPHO syndrome.
Article in American journal of clinical and experimental immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.
- [Diagnosis and treatment of chronic nonbacterial osteitis (CNO) and SAPHO syndrome : Implications of the current consensus recommendations of an international commission of experts for German rheumatology].Zeitschrift fur Rheumatologie · 2026Guideline
- What Is New and What Is Next for SAPHO Syndrome Management: A Narrative Review.Journal of clinical medicine · 2025Review
- New Insights in the Treatment of SAPHO Syndrome and Medication Recommendations.Journal of inflammation research · 2022Review
- SAPHO syndrome: pathogenesis, clinical presentation, imaging, comorbidities and treatment: a review.Postepy dermatologii i alergologii · 2021Review
- New Insights into Adult and Paediatric Chronic Non-bacterial Osteomyelitis CNO.Current rheumatology reports · 2020Review
- SAPHO: has the time come for tailored therapy?Clinical rheumatology · 2020Review
- Synovitis, acne, pustulosis, hyperostosis, and osteitis syndrome: review and update.Therapeutic advances in musculoskeletal disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo explore the application and efficacy of TNF-α inhibitors in the treatment of SAPHO syndrome.
methodsTwo cases of refractory SAPHO syndrome were successfully treated with etanercept. And pain scores, laboratory parameters and functional index were used to judge the efficacies. Literature was also systemically reviewed.
resultsBoth patients achieved marked clinical remission. There was no obvious toxic or adverse response.
conclusionEtanercept has rapid and definite efficacies in the treatment of patients with refractory SAPHO syndrome.
Indexed as
Identifiers
28078192PMC5218853W2578402903What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.